7 December 2024 - The accelerated approval pathway, which was established in 1992, has expedited approvals of drugs for serious and life-threatening diseases, with decisions being made on the basis of an intermediate clinical end point or a surrogate end point that is reasonably likely to predict clinical benefit.
When confirmatory trials don’t verify a drug’s clinical benefit or there are other legal grounds for withdrawal, the FDA may withdraw the approval.